ABC-DS Policies for Publications



POLICIES FOR PUBLICATIONS: Alzheimer’s Biomarkers Consortium on Down Syndrome (ABC-DS): Publications and Ancillary Studies Committee(Adapted from parallel policies developed by the DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN))As of 12/21/2019TABLE OF CONTENTSPagesRole & Structure of the Publications and Ancillary Studies Committee….…….……. 1B. General Principles Guiding Access to ABC-DS Data/Biospecimens………………… 2C. Request/Approval Process……………………………………….…………………………... 2 – 4D. Available Data/Resources………………………………….………………………………... 5E. Expectations When Accepting ABC-DS Data and Biospecimens………….…………... 5 Appendix 1: Notifications, Manuscript Review and Authorship………….…………............ 6 - 7 Appendix 2. ABC-DS Data Use Agreement………….…………............................................. 8 - 10 Appendix 3. ABC-DS Manuscript Citations………….…………............................................ 11 Appendix 4. Acknowledgement List for ABC-DS Publications………….…………............ 12 - 14ROLE & STRUCTURE OF THE PUBLICATIONS AND ANCILLARY STUDIES COMMITTEEThe charge of this committee will be: (a) to develop policies and procedures relevant to data analysis and determination of authorship for publications or presentations based on findings generated by ABC-DS research activities, (b) to develop policies and procedures regarding the sharing of ABC-DS generated data with investigators who are not collaborating directly in the conduct of ABC-DS research activities, (c) to establish a distinct subcommittee to develop and implement policies for reviewing and adjudicating requests by outside investigators for access to biospecimens collected by ABC-DS, and (d) to oversee implementation of these policies and procedures throughout the period of active ABC-DS funding. These policies must address the specific goal of making ABC-DS data and samples available to the wider community of interested investigators while recognizing fully the contributions of ABC-DS investigators, consistent with relevant ethical guidelines within their respective fields. Effectively balancing these priorities will support broader collaborations demonstrating promise of advancing knowledge about the association between Down syndrome and Alzheimer’s disease, specifically, and about Alzheimer’s disease more generally. The goal is to support effective and timely dissemination of ABC-DS findings, both by the ABC-DS team of investigators (NiAD and ADDS) and the broader community of interested scientists and clinicians. The Publications and Ancillary Studies Committee (herein referred to simply as the “Committee”) will consist of two Co-Chairs. The Co-Chairs will be Co-PI’s from each of the affiliated programs (NiAD and ADDS) funded through grants (U01 AG051406 and U01 AG051412, respectively) from the National Institute on Aging (NIA) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Membership will also be approximately equally divided among the teams of UO1 investigators to ensure fair representation of both the programs and the disciplines involved. Three additional members from each UO1 will serve terms of up to 3 years, with no two members from the same UO1 representing the same scientific discipline. Terms will be renewable and membership will be determined by the Co-Principal Investigators of the respective grants. The Committee will meet as needed to address its responsibilities as enumerated below.GENERAL PRINCIPLES GUIDING ACCESS TO ABC-DS DATA/BIOSPECIMENSSeveral principles guide the policies of this ABC-DS Committee. First, the contributions of the individuals responsible for designing and conducting studies must be recognized. Second, allocation of recognition for professional contributions to advancing this multidisciplinary work must be distributed in a fair and equitable way. Third, criteria for that recognition must be inclusive, understanding the ethical principles that guide such decisions across the multiple scientific and professional disciplines represented within the ABC-DS team of investigators. Fourth, the development and application of these policies must be transparent. The following policies address: (a) the process for allocating responsibilities and determining authorship roles within the ABC-DS community of investigators, (b) standards regarding security/confidentiality, (c) the process by which investigators outside of the ABC-DS community proper can request access to program-generated data and tissue samples, and (d) the processes involved in review of those requests. These policies, along with the Committee structure, will be subject to periodic review by the Co-PI’s of the two UO1s involved in consultation with NIH colleagues. Revisions will be made as needed to ensure that its activities continue to serve the needs of the project as efficiently and effectively as possible.REQUEST/APPROVAL PROCESSIntroduction. The intent of the resource sharing plan for the ABC-DS study is to establish a process for rapid public access to all data, without embargo, and for requesting access to the biospecimens by all qualified scientific investigators. The resource sharing plan outlines the methods for disseminating this information in a way that ensures anonymity to participants, responsible use of limited resources, assurance of a level of quality of data that adheres to the current standards of collection, and quality control and that complies with federal standards for the sharing of research data. It is the intention of the ABC-DS leadership that the data collected through the ABC-DS study be released as rapidly as possible to accelerate the understanding of AD in Down syndrome (DS) and in accordance with RFA-AG-15-011.The Committee is the primary governing body of the combined NiAD and ADDS studies charged with the primary oversight of the ABC-DS resource sharing plan. As part of this plan, all participants have been made aware in the consent forms that the information collected as part of this study will be made available to the scientific community for research purposes. However, any information shared will be de-identified to remove any links to personal identifiers prior to the sharing of any data.Additionally, the NiAD and ADDS studies have developed collaborative agreements with the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) whereby a biospecimen from each participant will be processed and made available to investigators per NCRAD policies.Access to Data/Resources. The Committee will follow full transparency for the process of providing access to ABC-DS data. The goal is to ensure that impartial methods are established in an inclusive manner to the research community. However, data security, participant anonymity and data quality are of paramount importance and will serve as a foundation for these guidelines. Additionally, because of the limitations of certain resources, the process for evaluating requests may differ, based on the material requested. The Committee will review all requests to ensure protection of the data, scientific merit and likelihood of success of the requesting parties in achieving the stated goals of the proposed study. However, because the intention of the resource sharing plan for ABC-DS is to release data in a rapid fashion, an exhaustive review of every request may not be feasible. IRB approval from the investigator’s institution will be requested if required by the local institution.Data/Biospecimen request form. An online data/biospecimen request form must be completed at the link indicated. Each request will specify the target subsample characteristics along with data elements required for planned analyses, including essential demographic and clinical information.Sharing of Genotype and other data. Investigators performing sequencing and/or array studies on biological samples obtained from the ABC-DS will need to provide written evidence of compliance/cooperation with current NIH policies regarding data sharing. Requests for biospecimens. A major goal of the ABC-DS project is the creation of a participant registry, database and biospecimen repository to support research focused on biomarkers of risk for AD, its clinical progression, and therapeutic targets for adults with DS and, by extension, for the broader population at risk. The Committee will review and process requests from qualified investigators seeking access to biospecimens generated through ABC-DS activities and banked for this purpose (including samples deposited at NCRAD). These biospecimens include cerebrospinal fluid, DNA, plasma, and serum. Restrictions on Access to Biospecimens. Biospecimens from ABC-DS participants cannot be used for exploratory research. Unless a case can be made that the proposed research can only be performed in the DS population, investigators seeking access to this resource must first demonstrate the hypothesized effect in analogous biospecimens from more readily available sources without DS (e.g., sporadic AD) or in an appropriate and convincing model system.Authority. Biospecimens shared with investigators will remain under the authority of the Committee. Investigators receiving ABC-DS generated biospecimens acknowledge this authority and will only use the materials in accordance with the ways approved by the Committee. Third party sharing that is not described within the approved protocol is not permitted without further explicit review and approval. A Material Transfer Agreement (MTA) must be fully executed with all appropriate ABC-DS parties before biospecimens can be released.Unless approved for a longer period, all requests will be "active" for a maximum of 18 months or until the number of approved samples has been provided, whichever comes first.Disclaimer regarding sample safety. ABC-DS generated samples have NOT been screened for infectious agents. Investigators and their staff/colleagues must take appropriate precautions and responsibility for ensuring safety resides within the laboratories receiving these samples.Review Process. Given the special and limited nature of this resource, a distinct Biospecimen Sharing Subcommittee (BSS) will be established to provide an additional level of review for sharing of ABC-DS generated biological samples. Approval of the BSS will be required in addition and prior to approval by the Committee. Requests for biospecimens must include details regarding both the samples and data elements to accompany the samples. After initial review by the Committee, all requests are assigned to the BSS composed of two to three ABC-DS Co-PI’s or Co-I’s with expertise most relevant to the research proposed and with first-hand knowledge of the inventory of banked samples and existing obligations for sample sharing/distribution (both within the ABC-DS team and with outside investigators). Typically, reviews will be completed within 60 days. Criteria for review include:Scientific merit, technical soundness and feasibilityAppropriateness for the DS population as evidenced by demonstration of preliminary data from studies of non-DS human populations or compelling model systems or justification why this study can only be done in the DS population (e.g., examining the effect of trisomy 21 on the measure of interest).Credentials of requesting investigator(s) Likelihood of successful completion of the proposed researchFit with the goals and specific aims of the ABC-DS proposalsRelationship of the proposed research to activities already in progressAvailability/burden on biospecimen resourcesBurden on other ABC-DS resourcesTo ensure that the work conducted by ABC-DS investigators in acquiring, preparing and storing ABC-DS data/biospecimens is appropriately acknowledged and credited, a procedure for acknowledgment and authorship will be provided as well. Additionally, to foster collaboration and acknowledge the work done by the performance sites in acquiring data, the Committee will encourage contact between ABC-DS investigators and outside investigators proposing ancillary studies to discuss possible collaboration on any proposed project that aligns closely with work being done by ABC-DS investigators. Final approval of requests for sharing of data or samples will be contingent on receipt of a signed agreement regarding the terms of use, as specified below. Tracking Requests. The number, type and disposition of requests will be tracked by the Committee and a data/biospecimen sharing report generated to allow progress to be monitored. Data/Sample Provision. Following review, approval and full execution of appropriate DUA or MTA, appropriate data files for sharing will be provided and transmitted to the lead investigator. These files will identify individual cases by a unique case/project to maintain confidentiality, but linkage to the original data file will be possible to ensure that any questions regarding the accuracy of shared data can be resolved. Image data will be available to approved investigators in raw and post-processed formats. Biospecimens will be provided, consistent with approved protocols, which must include explicit indications of handling and shipping requirements.Biospecimens and data may also be shared with commercial entities with the possibility that new products may be developed. ABC-DS participants will receive no financial compensation in such cases, and consent forms must also provide clear and appropriate notification of this stipulation when applicable.Outreach. Interested research communities will be informed of the scope of ABC-DS activities, data available for sharing, banked biological biospecimens, and procedures for requesting access to ABC-DS resources through a project website, through dissemination of information at scientific/professional conferences, and through an acknowledgment to be included in all ABC-DS generated publications. AVAILABLE DATA/RESOURCESBelow is a list of the general categories of information that will be collected and processed through ABC-DS and made available to qualified investigators.Clinical: Demographic information, medications, cognitive assessments, functional evaluations.Genetic: APOE genotype; high-density SNP data on chromosome 21 and genome-wide genotyping outside chromosome 21.Imaging: MRI-T1 weighted imaging, FLAIR, DTI, resting state fMRI BOLD, T2* Gradient Echo, pulsed ASL; PET- [C-11]PiB (50-70 min)(from NiAD), [F-18]AV-45 (from ADDS), [F-18]AV-1451 (80-100 min) and FDG (30-60 min)(from NiAD).Biospecimens: This includes cerebrospinal fluid (Aβ1-40, Aβ1-42, total tau and phosphorylated tau (ptau181)); multi-analyte assay of plasma proteins and lipids associated with neurodegenerative disorders (Myriad RBM (Austin, TX), Human NeuroMAP analysis) EXPECTATIONS WHEN ACCEPTING ABC-DS DATA AND BIOSPECIMENSAll investigators receiving ABC-DS-generated resources will be required to read and sign a data use agreement (DUA) patterned closely after that used by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (shown below in Appendix 2 and modified with the permission of the ADNI PI, Michael Weiner – who is a consultant to NiAD).Acceptance of ABC-DS generated data or samples obligates the recipient to cite/reference the grant(s) supporting the original collection in any presentation or publication that may result. Should publications result from the use of ABC-DS data now or in the future, the recipient agrees to notify the ABC-DS Committee on Publication and Ancillary Studies with details (reference or PubMedCentral ID#) and provide a copy of the publication. Note that these publications require compliance with National Institutes for Health (NIH) public access policies.Should funding of a future grant application result from any project utilizing ABC-DS data or biological samples, the lead investigator commits to notifying at least one ABC-DS Co-PI with details equivalent to what is provided in the NIH Reporter system (grant title, sponsor, number, budget and period of support, Abstract).No sharing of ABC-DS generated data or biospecimens with a third party is allowed without explicit approval of the Committee.Costs associated with sharing data or biospecimens with investigators who are not members of the ABC-DS team will be paid by those investigators.Recipients of ABC-DS generated data/biospecimens will provide evidence of IRB approval for receiving coded data/biospecimens (without access to identifiers) or documentation of the IRB’s exemption decision.Data generated by investigators receiving ABC-DS generated biospecimens will be considered the intellectual property of those investigators, but they will be expected to adhere to NIH guidelines and requirements for data sharing.APPENDIX 1: NOTIFICATIONS, MANUSCRIPT REVIEW AND AUTHORSHIPThe ABC-DS Policies for Publication applies to all public and scientific communication of unpublished data that result from any ABC-DS-related activity. All investigators must abide by established policies and procedures. When conflicts arise, a majority vote of the Co-PI’s of ABC-DS associated grants will adjudicate all disputes and decisions will be munications from the ABC-DS team may be classified as press releases, interviews, public web site postings, presentations (includes poster and accompanying abstract) or publications. One of the Committee Co-Chairs should be notified of requests for all such communications prior to making any commitment to move ahead with that activity.Manuscripts to be submitted by an ABC-DS team member for publication in a scientific or professional journal are subject to prior internal review. This policy encourages collegial interactions and ensures that quality of submissions is maintained. Documentation of internal review is the responsibility of the lead author and must be provided to the Committee at the time of notification of submission. In cases where the lead author is unsure of appropriate internal reviewers, the draft manuscript can be submitted to one of the Co-Chairs of the Committee at least 4 weeks prior to submission and internal reviewers will be assigned.Publication Authorship. The overarching considerations for publications arising from ABC-DS activities are collaboration and inclusiveness. For publications based on the use ABC-DS generated data and/or tissue, an invitation to collaborate (meriting authorship) on the manuscript should be issued to all ABC-DS team members making substantive contributions to the work reported in that specific submission. In the vast majority of cases, activities involved in development of a publication will be supervised/coordinated/managed by the investigator assigned to take the lead role for the specific area of ABC-DS activity involved, and this individual will be responsible for determining authorship order. It will then be up to invitees to indicate whether or not they wish to be included. If so, prospective authors will be provided adequate opportunity for review prior to submission.Decisions regarding inclusion/exclusion will be made based on current standards of authorship responsibilities (e.g., contribute significantly to the conception, design, execution, and/or analysis and interpretation of data; participate in drafting, reviewing, and/or revising the manuscript for intellectual content). In some situations, entire teams (or large numbers) of ADDS, NiAD or ABC-DS investigators may meet these criteria and, in these cases, they all should be included as authors. For some journals, policies may require the author line to include a more limited number of individuals, and in those situations, it is permissible to have the masthead read “First Author, Other Authors and the ABC-DS (or ADDS or NiAD, as appropriate) Group” with the individual members listed in an appropriate section of the presentation or manuscript. Ordering of authors will be the responsibility of the lead author(s). Should conflicts arise, appeal can be made to the ABC-DS Co-Principal Investigators, who, by majority vote, will decide the issue.In the case of ancillary studies led by non-ABC-DS investigators, specific language should be included in each publication that acknowledges that contribution to the effort, consistent with relevant authorship practices within the lead discipline. Invited ABC-DS authors must be afforded opportunity to review such manuscripts prior to submission. An acknowledgement of the grant(s) supporting the ABC-DS should be included in all cases (see illustrative paragraph at the end of this document). Published Abstracts. Authorship rules for abstracts accompanying presentations are as stated above but may have limitations on the number of authors permitted. If authorship is limited or it is impractical to include all authors, then “The ABC-DS (or NiAD/ADDS) Group” would be listed as an author. For abstracts, it will not be necessary to include the full list of members, but the presentation should include an appropriate acknowledgment naming all contributors to the work presented.Other Personnel as an Author. The writing group for a manuscript may include trainees, study coordinators, and other personnel as authors, providing that each author has met ethical standards commensurate with authorship. The lead author will be responsible for decisions regarding inclusion and ordering. However, the same policies for resolving disagreements will apply.Press releases, interviews and informal presentations: These classes of activities typically do not have authors, although attribution to the ABC-DS or to specific individuals often occurs. When authorship is appropriate, rules will be the same as for abstracts and formal presentations. For informal presentations at local meetings and for “in-house” meetings/seminars, acknowledgment of the ABC-DS (or NiAD/ADDS, as appropriate) is expected. For interviews and press releases, prior approval by the group of ABC-DS Co-PI’s is mandatory. In addition, adherence to all requirements of home institutions and funding agencies is mandatory.Designation of ABC-DS team members in Supplements to Publications: Some journals allow inclusion of supplemental material along with manuscript submission. Supplemental material for ABC-DS publications can and should recognize contributions of all appropriate ABC-DS team members, including individuals who may not have been included as authors of the corresponding manuscript. Organizations providing substantive support to the work described should also be recognized.APPENDIX 2. ABC-DS DATA USE AGREEMENTI have read the ABC-DS Policies for Publications document located at request access to data collected by the ABC-DS study for the purpose of scientific investigation, teaching or the planning of clinical research studies. Upon review and approval of access to data and/or biospecimen, I acknowledge and agree to the following terms.I will receive access to de-identified data and will not attempt to establish the identity of or attempt to contact any of the ABC-DS participants.I will not attempt to make direct contact with ABC-DS investigators or staff at sites concerning the specific results of individual participants.I will not further disclose these data beyond the uses outlined in this agreement and my data use application and understand that redistribution of data in any manner is prohibited.I will require anyone on my team who utilizes these data, or anyone with whom I share these data to comply with this data use agreement.I will accurately provide the requested information for persons who will use these data and the analyses that are planned using these data.I will respond promptly and accurately to annual requests to update this information.I will comply with any rules and regulations imposed by my institution and its institutional review board in requesting these data.If I publish abstracts using data from the ABC-DS study, I agree to the following:I will cite ABC-DS as the source of data and the ABC-DS funding sources (including grant numbers) in the abstract as space allows.Acknowledgement of ABC-DS will not be cited in the authorship line of the abstract.If I publish manuscripts using data from the ABC-DS study, I agree to the following:On the by-line of the manuscript, after the named authors, I will include the phrase “for the Alzheimer’s Biomarker Consortium on Down Syndrome study*” with the asterisk referring to the following statement and list of names:*Data used in preparation of this article were obtained from the Neurodegeneration in Aging Down syndrome (NiAD) database (niad.loni.usc.edu) and Alzheimer’s Disease in Down Syndrome (ADDS) database. As such, the investigators within the ABC-DS study contributed to the design and implementation of ABC-DS and/or provided data but did not participate in analysis or writing of this report. A complete listing of ABC-DS investigators can be found at: will include language similar to the following in the methods section of my manuscripts in order to accurately acknowledge data gathering by the ABC-DS personnel. Depending upon the length and focus of the article, it may be appropriate to include more or less than the example below, however inclusion of some variation of the language shown below is mandatory.The preparation of this manuscript was made possible from data obtained by the Alzheimer’s Biomarkers Consortium –Down Syndrome (ABC-DS), a longitudinal study of Alzheimer Disease biomarkers in adults with Down syndrome supported by grants from the National Institute on Aging (NIA) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The primary goal of ABC-DS is to understand the factors that moderate the relationship between Aβ, neurodegeneration and dementia in DS and biomarkers for those factors that could be critically important in the design of effective therapeutic trials for AD, not only in DS, but in the general population as well. The Principal Investigators of the ABC-DS study are Benjamin Handen, PhD and William Klunk, MD, PhD, (University of Pittsburgh), Bradley Christian, PhD (University of Wisconsin-Madison), Nicole Schupf, PhD, Dr PH (Columbia University), and Ira Lott, MD and Wayne Silverman, PhD (UC Irvine). The ABC-DS study is a collaboration of field sites at Pittsburgh, Madison, Phoenix (Banner Alzheimer’s Institute; Marwan Sabbagh, MD), the University of Cambridge (Shahid Zaman, MD), Washington University (Beau Ances, MD, PhD and John Constantino, MD), Columbia University, Harvard University (Florence Lai, MD and H Diana Rosas, MD) and UC Irvine. ABC-DS was established to collect longitudinal clinical, neuroimaging, genetic and biofluid markers in approximately 400 participants with DS who were primarily non-demented.I will acknowledge the ABC-DS study in the support acknowledgement section of the manuscript using language similar to the following:"Data collection and sharing for this project was supported by The Alzheimer’s Disease Biomarker Consortium on Down Syndrome (ABC-DS) funded by the National Institute on Aging (NIA) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1 AG051406 and UO1 AG051412). The authors thank the adults with Down syndrome volunteering as participates in this study for their invaluable contributions to this work, along with their service providers and families. Finally, the authors thank the staff contributing their many hours of support to this work, including (with names of specific individuals provided, as determined by the lead author(s).”I will submit all manuscripts to the ABC-DS Steering Committee prior to submitting to a journal. This review will not be a scientific review, but is intended to ensure that sections 7-12 above are correctly implemented. The ABC-DS Steering Committee will maintain confidentiality of the manuscript and will complete its review within 2 weeks.I will ensure that Investigators who utilize ABC-DS data use appropriate administrative, physical and technical safeguards to prevent use or disclosure of the data other than as provided for by this Agreement.I will report any use or disclosure of the data not provided for by this Agreement of which I become aware within 15 days of becoming aware of such use or disclosure.IMPORTANT NOTE: It is the policy of the ABC-DS to make analyzed data available to investigators as quickly as possible. However, data analysis for this project is expected to take years as methods for analysis of these datasets evolve. Therefore, I understand that any processed data that I download might be preliminary and that results may change as new methods of analysis are implemented. I will familiarize myself with the analysis methods so that I am aware of the limitations of these data prior to using them for scientific purposes.Finally, because “preliminary data” will be posted on the database, in the event that I download data from the ABC-DS databases for the purposes of analysis and future publication in the form of abstracts and/or publications, I will note the version of the data I download, and I will check the databases to determine if updated data has been provided prior to submission of any material for publication.I understand that failure to abide by these guidelines will result in termination of my privileges to access data from the ABC-DS study.__________________________________________________________Electronic Signature of User APPENDIX 3. ABC-DS MANUSCRIPT CITATIONSBy-line: Include the phrase “for the ABC-DS*” with the asterisk referring to the following statement and list of names: *Data used in preparation of this article were obtained from the Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS) database (). As such, the investigators within ABC-DS contributed to the design and implementation of ABC-DS and/or provided data but did not participate in analysis or writing of this report. A complete listing of ABC-DS investigators can be found at Section: Refer to the Data Use Agreement, section 11, for the language which should be used to acknowledge the gathering of data by the ABC-DS personnel.Acknowledgement Section: Refer to the Data Use Agreement, section 12, for the language that should be used to acknowledge the ABC-DS study.APPENDIX 4. ACKNOWLEDGEMENT LIST FOR ABC-DS PUBLICATIONSThe Publications and Ancillary Studies Committee, in keeping with the publication policies adopted by the ABC-DS Steering Committee, here provide lists for standardized acknowledgement. The list consists of ABC-DS Site Investigators and personnel. All papers, including methodological papers, should have an acknowledgement list that consists of the FULL list.ABC-DS Investigator Teams by SiteColumbia University Medical Center:Nicole Schupf, PhD, DrPHAdam M. Brickman, PhDHoward F. Andrews, PhDJoseph Hyungwoo Lee, PhDKaren Bell, MDLawrence Honig, MDWilliam Charles Kreisl, MDLorraine Clark, PhDPatrick Lao, PhDBadri Vardarajan, PhDBatool Rizvi, MSAubrey Johnson, BAGeorgetown University Amrita Cheema, PhDHackensack University Medical CenterBenjamin Tycko, MD, PhDJohns Hopkins University, Bloomberg School of Public HealthMei-Cheng Wang, PhD Yuchen Yang, MSMass General Hospital/HarvardHerminia Diana Rosas, MDFlorence Lai, MDJulie C. Price, PhDMargaret Pulsifer, PhDCourtney Jordan, BSN, RN, CPNNusrat Jahan, BA New York State Institute of Basic ResearchSharon J. Krinsky-McHale, PhDDeborah Pang, MPHUniversity of California IrvineIra T. Lott, MD Wayne P. Silverman, PhDElizabeth Head, PhDMark Mapstone, PhDDavid Keator, PhDMichael A. Yassa, PhDChristy Hom, PhDMinodora Totoiu, MD, PhDEric W. Doran, MSDana D. Nguyen, PhDMithra Sathishkumar, MSAlicia Hernandez, AAUniversity of Cambridge, UKShahid Zaman, MD, PhDIsabel Clare, PhDGuy Williams, PhDTimothy Fryer, PhD Young Hong, PhDFranklin Aigbirhio, PhDVictoria Lupson, PhDMonika Grigorova, MScUniversity of North Texas Health Sciences CenterSid O’Bryant, PhDFan Zhang, PhDJames Richard Hall, PhDMelissa Petersen, PhDUniversity of PittsburghBenjamin L. Handen, PhDWilliam E. Klunk, MD, PhDAnn D. Cohen, PhDCharles Laymon, PhDDana L. Tudorascu, PhDPeter Bulova, MDMilos D. Ikonomovic, MDEleanor Feingold, PhDJulia Kofler, MDNeelesh Nadkarni, MDDavneet Singh Minhas, PhDHoward J. Aizenstein, MD, PhDEleanor Feingold, PhDChester A. Mathis, PhDRameshwari Tumuluru, MDLeslie Dunn, MPHJoni Vander Bilt, MPHCathleen Wolfe, MEdUniversity of WisconsinBradley T. Christian, PhDSigan L. Hartley, PhDSterling C. Johnson, PhDRasmus M. Birn, PhDAndrew Alexander, PhDMatthew Zammit, MSBrianna Gambetti, BSAleshia Cole, NPRenee Makuch, BAWashington University, St LouisBeau M. Ances, MD, PhDJohn N. Constantino, MDDesiree A. White, PhDOlga Del Rosario MDElizabeth Westerhaus, MAAnne Fagan, PhD Rachel Henson, PhDBarrow Neurological InstituteMarwan N. Sabbagh, MD Sandy Quintanilla, AA ABC-DS InfrastructureAlzheimer’s Therapeutic Research Institute (ATRI)Paul S. Aisen, MDMichael Rafii, MD, PhDGustavo Jimenez, MBSSarah Walter, MScDevon Gessert, BSRenarda Jones, MSLaboratory of Neuro Imaging (LONI)Arthur W. Toga, PhDKaren Crawford, MLISNational Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD)Tatiana M. Foroud, PhDKelley Faber, MS, CCRCKristi Wilmes, MS, CCRPAriel Quickery, MSMadison Donoho, BSAging and Dementia Imaging Research (ADIR), Mayo ClinicGregory M. Preboske, MSBret J. Borowski, RTKejal Kantarci, MDClifford R. Jack Jr, MDPET QC Lab University of MichiganRobert A. Koeppe, PhD ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download